TY - JOUR T1 - Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3747 AU - Kensuke Kataoka AU - Hiroyuki Taniguchi AU - Yasuhiro Kondoh AU - Tomoki Kimura AU - Toshiaki Matsuda AU - Toshiki Yokoyama AU - Yasuhiko Yamano AU - Yoshio Nakahara AU - Mitsuaki Yagi Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3747.abstract N2 - Background: The aim of this study was to find out which patients benefit from pirfenidone (PFD).Methods: From December 2008 to November 2012, the clinical records of patients with idiopathic pulmonary fibrosis (IPF) treated with PFD were reviewed in Tosei General Hospital. Patients with relative declines in forced vital capacity (FVC) (FVCbaseline-FVCone-year/FVCbaseline) of less than 10% after one-year treatment were defined as “non-worsened”, while those of more than 10% and/or death were defined as “worsened”. The clinical features were compared between the two groups.Results: The study population (n=107) was composed of 82 males and 25 female with mean age of 67.0±7.5 years. Average baseline FVC and diffusing capacity of the lung for carbon monoxide (DLco) in the study population was 67.2±17.1% and 44.4±17.7% respectiverly. “Non-worsen” (n=49, 45.8%) had higher means of FVC, 6-minute walk test (6MWT) distance, the lowest oxygen saturation in the 6MWT and Baseline Dyspnea Index (BDI) at baseline (p=0.0001, 0.0259, 0.0470, 0.0080, respectively), and lower means of St. George's Respiratory Questionnaire (SGRQ) scores at baseline (p=0.0069).Conclusion: Milder impairments in multidimensional evaluations such as FVC, dyspnea grade, 6MWT and exercise hypoxemia, and health related QOL were predictors of PFD efficacy in IPF. ER -